Observational studyBMC pulmonary medicine2019
Indwelling pleural catheters for malignancy-associated pleural effusion: report on a single centre's ten years of experience.
Observational study in BMC pulmonary medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Incidence of complications from indwelling pleural catheter for pleural effusion: A meta-analysis.Clinical and translational science · 2023Pooled it
- Indwelling pleural catheter for malignant pleural effusion: a real-life experience in a tertiary centre with a dedicated pleural service in the Republic of Ireland.Irish journal of medical science · 2025Article
- Clinical outcomes of caregiver-led indwelling pleural catheter care and drainage at a Singapore tertiary referral hospital.Journal of thoracic disease · 2025Article
- A patient-centred approach to malignant pleural effusion.European clinical respiratory journal · 2025Review
- Article
- Indwelling tunneled pleural catheter infections and host related factors.Respiratory medicine · 2024Article
- Indwelling pleural catheter infection and colonisation: a clinical practice review.Journal of thoracic disease · 2024Review
- The Treatment of Malignant Pleural Effusion With Permanent Indwelling Pleural Catheters.Deutsches Arzteblatt international · 2022Article
- Diagnosis and Management of Malignant Pleural Effusion: A Decade in Review.Diagnostics (Basel, Switzerland) · 2022Review
- Percutaneous Ultrasound-guided Pigtail Catheter for Pleural Effusions: Efficacy and Safety.Oman medical journal · 2021Article
- Predicting the survival in patients with malignant pleural effusion undergoing indwelling pleural catheter insertion.Annals of thoracic medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecurrent pleural effusion is a common cause of dyspnoea, cough and chest pain during the course of malignant diseases. Chemical pleurodesis had been the only definitive treatment option until two decades ago. Indwelling pleural catheters (IPC) emerged as an alternative, not only assuring immediate symptom relief but also potentially leading to pleurodesis in the absence of sclerosing agents.
methodsIn this single-centre retrospective observational study patient characteristics, procedural variables and outcome in a large population of patients with IPC in malignancy were evaluated and prognostic factors for pleurodesis were identified.
resultsFrom 2006 to 2016, 395 patients received 448 IPC, of whom 121 (30.6%) had ovarian, 91 (23.0%) lung and 45 (11.4%) breast cancer. The median length of IPC remaining in place was 1.2 months (IQR, 0.5-2.6), the median survival time after insertion 2.0 months (IQR, 0.6-6.4). An adequate symptom relief was achieved in 94.9% of all patients, with no need for subsequent interventions until last visit or death. In patients surviving ≥30 days after IPC insertion, pleurodesis was observed in 44.5% and was more common in patients < 60 years (HR, 1.72; 95% CI, 1.05-2.78; p = 0.03). The use of an additional talc slurry via the IPC was highly predictive for pleurodesis (HR 6.68; 95% CI, 1.44-31.08; p = 0.02). Complications occurred in 13.4% of all procedures (n = 60), 41.8% concerning infections (local infections at the tunnel/exit site (n = 14) and empyema (n = 11)), and 98.3% being low or mild grade (n = 59). Complication rates were higher in men than women (18.6 vs. 12.4%, p = 0.023).
conclusionHigh efficacy in symptom relief and a favourable safety profile confirm IPC as suitable first line option in most malignant pleural effusions. The study presents the largest dataset on IPC in gynaecologic cancer to date. Gender-specific differences in complication rates warrant further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.